title: Laser in situ keratomileusis for myopia up to -11 diopters with up to -5 diopters of astigmatism with the summit autonomous LADARVision excimer laser system.
abstract: OBJECTIVE
  To assess the safety and effectiveness of the Summit Autonomous LADARVision active tracking narrow beam excimer laser system for laser in situ keratomileusis (LASIK) correction of myopia and astigmatism.
  
  
  METHODS
  A multicenter, prospective noncomparative case series.
  
  
  METHODS
  This cohort consisted of 177 eyes corrected for spherical myopia up to -11 diopters (D) and 170 eyes corrected for myopia up to -11 D spherical equivalent with astigmatism up to -5 D.
  
  
  METHODS
  Treatments were performed at four sites in the United States using a 6-mm optic zone for spherical myopes and a 5.5-mm optic zone with a 1-mm blend for astigmats.
  
  
  METHODS
  Visual acuity, subjective refraction, vector analysis, subject satisfaction, intraocular pressure, complications, and adverse reactions.
  
  
  RESULTS
  Six-month follow-up was available on 157 spherical eyes and 113 astigmatic eyes. For spherical myopes, uncorrected visual acuity (UCVA) was 20/20 or better in 60.5%, 20/25 or better in 80.3%, and 20/40 or better in 93.9%. The mean spherical equivalent was -0.29 +/- 0.45 D with 75.2% +/- 0.50 D and 94.9% +/- 1.00 D of intended. A loss of two lines of best spectacle-corrected visual acuity (BSCVA) occurred in 0.6%, and no eyes lost greater than two lines of BSCVA. For astigmatic myopes, UCVA was 20/20 or better in 52.0%, 20/25 or better in 74.5%, and 20/40 or better in 94.1%. The mean spherical equivalent was -0.23 +/- 0.49 D with 75.2% +/- 0.50 D and 95.6% +/- 1.00 D of intended. A loss of two lines of BSCVA occurred in 0.9%, and no eyes lost greater than two lines of BSCVA. Vector analysis showed that 99% of the intended cylinder was corrected on average with a mean angle of error of 4.2 degrees. Refractive stability was achieved between 1 and 3 months in 97.5% of spherical eyes and 99.4% of astigmatic eyes and confirmed between 3 and 6 months in 100% of both spherical and astigmatic eyes.
  
  
  CONCLUSIONS
  Eyes treated for myopia up to -11 D of spherical equivalent with or without astigmatism up to -5 D show early refractive stability, good UCVA outcomes, no significant loss of BSCVA, accurate correction of astigmatism, and slight undercorrection without a change from the photorefractive keratectomy algorithm and with a single treatment.
authors.affiliation: Southern Vision Institute, New Orleans, Louisiana, USA.
authors.forename: M B
authors.initials: MB
authors.lastname: McDonald
authors.forename: J D
authors.initials: JD
authors.lastname: Carr
authors.forename: J M
authors.initials: JM
authors.lastname: Frantz
authors.forename: A M
authors.initials: AM
authors.lastname: Kozarsky
authors.forename: E
authors.initials: E
authors.lastname: Maguen
authors.forename: A B
authors.initials: AB
authors.lastname: Nesburn
authors.forename: Y S
authors.initials: YS
authors.lastname: Rabinowitz
authors.forename: J J
authors.initials: JJ
authors.lastname: Salz
authors.forename: R D
authors.initials: RD
authors.lastname: Stulting
authors.forename: K P
authors.initials: KP
authors.lastname: Thompson
authors.forename: G O
authors.initials: GO
authors.lastname: Waring
mesh_terms: D000328:Adult; D000368:Aged; D001251:Astigmatism / Q000601:surgery*; D015331:Cohort Studies; D003315:Cornea / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000601:surgery*; D017060:Patient Satisfaction; D011183:Postoperative Complications; D011446:Prospective Studies; D012029:Refraction, Ocular; D012449:Safety; D016896:Treatment Outcome; D014792:Visual Acuity